Gocatamig

N/A

Report date: 2026/05/28 20:00:21

Base Information

Drug NameGocatamig
Drug Alias Nameanti-CD3/anti-DLL3/anti-HSA trispecific T-cell engager (Harpoon Therapeutics)triple anti-CD3/anti-DLL3/anti-HSA T-cell engager (Harpoon Therapeutics)Anti-DLL3 T Cell Engager (Harpoon Therapeutics)HPN-328MK-6070 +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionDelta-like protein 3 modulatorsAnti-CD3Anti-Serum albumin
TargetsDelta-like protein 3T cell surface glycoprotein CD3Serum albumin
Therapy Area/IndicationsSmall Cell Lung CarcinomaCarcinoma, Neuroendocrine
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanPoland +[18] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHarpoon Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesHarpoon Therapeutics IncDaiichi Sankyo Co LtdMerck Sharp & Dohme LLC +[4] 
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung CarcinomaCarcinoma, Neuroendocrine
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A